{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T12:15:20Z","timestamp":1789215320899,"version":"build-2803163510"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2001,6,1]],"date-time":"2001-06-01T00:00:00Z","timestamp":991353600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Diab Rep"],"published-print":{"date-parts":[[2001,6]]},"DOI":"10.1007\/s11892-001-0025-7","type":"journal-article","created":{"date-parts":[[2007,5,19]],"date-time":"2007-05-19T23:06:06Z","timestamp":1179615966000},"page":"133-139","source":"Crossref","is-referenced-by-count":5,"title":["Drugs for cardiovascular risk reduction in the diabetic patient"],"prefix":"10.1007","volume":"1","author":[{"given":"David S. H.","family":"Bell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"25_CR1","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/BF01223277","volume":"13","author":"AS Krolewski","year":"1977","unstructured":"Krolewski AS, Czyzyk A, Janeczko D, Kopczynski J: Mortality from cardiovascular disease among diabetics. Diabetologia 1977, 13:345\u2013350.","journal-title":"Diabetologia"},{"key":"25_CR2","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1007\/BF00281993","volume":"28","author":"T Jensen","year":"1985","unstructured":"Jensen T, Borch-Johnsen K, Kofoed-Enevoldsen A, Deckert T: Coronary artery disease in young type 1 (insulin-dependent) diabetic patients with and without diabetic nephropathy: incidence and risk factors. Diabetologia 1985, 28:590\u2013596.","journal-title":"Diabetologia"},{"key":"25_CR3","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/S0140-6736(88)92657-8","volume":"2","author":"JS Yudkin","year":"1988","unstructured":"Yudkin JS, Forrest RD, Jackson CA: Microalbuminuria as a predictor of vascular disease in non-diabetic subjects. Lancet 1988, 2:530\u2013533.","journal-title":"Lancet"},{"key":"25_CR4","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/0002-8703(86)90155-9","volume":"111","author":"DJ Lerner","year":"1986","unstructured":"Lerner DJ, Kannel WB: Patterns of coronary artery disease morbidity and mortality in the sexes: a 26-year follow-up of the Framingham population. Am Heart J 1986, 111:383\u2013390.","journal-title":"Am Heart J"},{"key":"25_CR5","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/S0140-6736(95)92118-4","volume":"346","author":"IF Godsland","year":"1995","unstructured":"Godsland IF, Stevenson JC: Insulin resistance: syndrome or tendency? Lancet 1995, 346:100\u2013103.","journal-title":"Lancet"},{"key":"25_CR6","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S0735-1097(98)00557-9","volume":"33","author":"KN Garratt","year":"1999","unstructured":"Garratt KN, Brady PA, Hassinger NL, et al.: Sulfonylurea drugs increase early mortality in patients with diabetes mellitus after direct angioplasty for acute myocardial infarction. J Am Coll Cardiol 1999, 33:119\u2013120.","journal-title":"J Am Coll Cardiol"},{"key":"25_CR7","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1053\/euhj.1998.1153","volume":"19","author":"JH O\u2019Keefe","year":"1998","unstructured":"O\u2019Keefe JH, Blackstone EH, Sergeant P, McCallister BD: The optimal mode of coronary revascularization for diabetes: a risk adjusted long-term study comparing coronary angioplasty and coronary bypass surgery. Eur Heart J 1998, 19:1696\u20131703.","journal-title":"Eur Heart J"},{"key":"25_CR8","first-page":"1515","volume":"83","author":"PS Johnson","year":"1998","unstructured":"Johnson PS, Levovitz HE, Coniff RF, et al.: Advantages of alphaglucosidase inhibition as monotherapy in elderly type 2 diabetic patients. J Clin Endocrinol Metab 1998, 83:1515\u20131522.","journal-title":"J Clin Endocrinol Metab"},{"key":"25_CR9","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1053\/euhj.1998.1242","volume":"20","author":"H Klepzig","year":"1999","unstructured":"Klepzig H, Kober G, Matter C, et al.: Sulfonylureas and ischemic preconditioning, a double-blind placebo controlled evaluation of glimepiride and glibenclamide. Eur Heart J 1999, 20:439\u2013446.","journal-title":"Eur Heart J"},{"key":"25_CR10","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1136\/bmj.321.7258.405","volume":"321","author":"IM Stratton","year":"2000","unstructured":"Stratton IM, Adler AI, Neil HA, et al.: Association of glycemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000, 321:405\u2013412. Showed that there was no threshold down to an A1c of 6.1%, below which cardiovascular events would not be reduced.","journal-title":"BMJ"},{"key":"25_CR11","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1136\/bmj.322.7277.15","volume":"322","author":"Kay-Tee Khaw","year":"2001","unstructured":"Khaw Kay-Tee, Wareham N, Luber R, et al.: Glycated hemoglobin, diabetes and mortality in men in Norfolk cohort of European Prospective Investigation of Cancer and Nutrition (EPIC-Norfolk). BMJ 2001, 322:15\u201318. Demonstrated that the lower the A1c the lower the risk for cardiac events even within the normal (nondiabetic) range for A1c.","journal-title":"BMJ"},{"key":"25_CR12","doi-asserted-by":"crossref","first-page":"2591","DOI":"10.1161\/01.CIR.91.10.2591","volume":"91","author":"JD Curb","year":"1995","unstructured":"Curb JD, Rodriquez BL, Burchfield CM, et al.: Sudden death, impaired glucose tolerance and diabetes in Japanese American men. Circulation 1995, 91:2591\u20132592.","journal-title":"Circulation"},{"key":"25_CR13","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/BF00400679","volume":"39","author":"H Ceriello","year":"1996","unstructured":"Ceriello H, Taboga C, Tonutti C, et al.: Post-meal coagulation activation in diabetes mellitus: the effect of acarbose. Diabetologia 1996, 39:469\u2013473.","journal-title":"Diabetologia"},{"key":"25_CR14","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1136\/bmj.314.7093.1512","volume":"314","author":"K Malmberg","year":"1997","unstructured":"Malmberg K: DIGAMI (Diabetes Mellitus, Insulin, Glucose Infusion in Acute Myocardial Infarction) prospective randomized study of intensive insulin treatment on longterm survival after acute myocardial infarction in patients with diabetes mellitus. BMJ 1997, 314:1512\u20131515.","journal-title":"BMJ"},{"issue":"suppl 1","key":"25_CR15","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/S0140-6736(98)90311-7","volume":"352","author":"MR Bristow","year":"1998","unstructured":"Bristow MR: Why does the myocardium fail? New insights from basic science. Lancet 1998, 352(suppl 1):8\u201314.","journal-title":"Lancet"},{"key":"25_CR16","doi-asserted-by":"crossref","first-page":"2626","DOI":"10.1161\/01.CIR.99.20.2626","volume":"99","author":"K Malmberg","year":"1999","unstructured":"Malmberg K, Norhammar A, Wedel H, et al.: Glycometabolic state at admission: important risk marker in mortality in conventionally treated patients with diabetes mellitus and acute myocardial infarction: long-term results from the Diabetes and Insulin-Glucose infusion in Acute Myocardial Infarction (DIGAMI) study. Circulation 1999, 99:2626\u20132632.","journal-title":"Circulation"},{"key":"25_CR17","doi-asserted-by":"crossref","first-page":"755","DOI":"10.2337\/diacare.15.6.755","volume":"15","author":"CJ Bailie","year":"1992","unstructured":"Bailie CJ: Biguanides and NIDDM. Diabetes Care 1992, 15:755\u2013772.","journal-title":"Diabetes Care"},{"key":"25_CR18","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/S0140-6736(98)07037-8","volume":"352","author":"UK Prospective Diabetes Study (UKPDS) Group","year":"1998","unstructured":"UK Prospective Diabetes Study (UKPDS) Group: Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998, 352:854\u2013865.","journal-title":"Lancet"},{"key":"25_CR19","first-page":"94","volume":"7","author":"CJ Bailie","year":"1999","unstructured":"Bailie CJ: New pharmacological approaches to glycemic control. Diabetes Rev 1999, 7:94\u2013113.","journal-title":"Diabetes Rev"},{"key":"25_CR20","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.2337\/diacare.23.12.1835","volume":"23","author":"M Frohlich","year":"2000","unstructured":"Frohlich M, Imhof A, Berg G, et al.: Association between C-reactive protein and features of the metabolic syndrome: a population-based study. Diabetes Care 2000, 23:1835\u20131839.","journal-title":"Diabetes Care"},{"key":"25_CR21","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1161\/01.CIR.101.11.1311","volume":"101","author":"RE Law","year":"2000","unstructured":"Law RE, Goetze S, Xi XP, et al.: Expression and function of PPARgamma in rat and human vascular smooth muscle cells. Circulation 2000, 101:1311\u20131318.","journal-title":"Circulation"},{"key":"25_CR22","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1210\/jcem.83.5.4932","volume":"83","author":"J Minamikawa","year":"1998","unstructured":"Minamikawa J, Tanaka S, Yamauchi M, et al.: Potent inhibitory effect of troglitazone on carotid arterial wall thickness in type 2 diabetes. J Clin Endocrinol Metab 1998, 83:1818\u20131820.","journal-title":"J Clin Endocrinol Metab"},{"key":"25_CR23","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1016\/S0735-1097(00)00895-0","volume":"36","author":"T Takagi","year":"2000","unstructured":"Takagi T, Akasaka T, Yamamuro A, et al.: Troglitazone reduces neointimal tissue proliferation after coronary stent implantation in patients with non-insulin dependent diabetes mellitus: a serial intravascular ultrasound study. J Am Coll Cardiol 2000, 36:1529\u20131535.","journal-title":"J Am Coll Cardiol"},{"key":"25_CR24","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1056\/NEJM199803053381003","volume":"338","author":"RO Estacio","year":"1998","unstructured":"Estacio RO, Jeffers BW, Hiatt WR, et al.: The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin dependent-diabetes and hypertension. N Engl J Med 1998, 338:645\u2013652.","journal-title":"N Engl J Med"},{"key":"25_CR25","doi-asserted-by":"crossref","first-page":"597","DOI":"10.2337\/diacare.21.4.597","volume":"21","author":"P Tatti","year":"1998","unstructured":"Tatti P, Pahor M, Byington RP, et al.: Outcome results of the fosinopril versus amlopidine cardiovascular events randomization trial (FACET) in patients with hypertension and NIDDM. Diabetes Care 1998, 21:597\u2013603.","journal-title":"Diabetes Care"},{"key":"25_CR26","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.2337\/diacare.21.12.2103","volume":"21","author":"RP Byington","year":"1998","unstructured":"Byington RP,Furberg CD, Craven TE, et al.: Isradipine in prediabetic hypertensive subjects. Diabetes Care 1998, 21:2103\u20132110.","journal-title":"Diabetes Care"},{"key":"25_CR27","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1136\/bmj.321.7258.412","volume":"321","author":"AI Adler","year":"2000","unstructured":"Adler AI, Stratton IM, Neil HA, et al.: Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ 2000, 321:394\u2013395.","journal-title":"BMJ"},{"key":"25_CR28","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1136\/bmj.317.7160.703","volume":"317","author":"UK Prospective Diabetes Group","year":"1998","unstructured":"UK Prospective Diabetes Group: Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998, 317:703\u2013713. [Published erratum appears in BMJ 1999, 318:329.]","journal-title":"BMJ"},{"key":"25_CR29","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1016\/S0140-6736(98)04311-6","volume":"351","author":"L Hansson","year":"1998","unstructured":"Hansson L, Zanchotti A, Carruthers SG, et al. (HOT Study Group): Effects of intensive blood pressure lowering and lowdose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomized trial. Lancet 1998, 351:1755\u20131762.","journal-title":"Lancet"},{"key":"25_CR30","doi-asserted-by":"crossref","unstructured":"The sixth report of the Joint National Committee on prevention, detection, evaluation and treatment of high blood pressure [no authors listed]. Arch Intern Med 1997, 157:2413\u20132446. [Published erratum appears in Arch Intern Med 1998, 158:573.]","DOI":"10.1001\/archinte.1997.00440420033005"},{"key":"25_CR31","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1136\/bmj.317.7160.713","volume":"317","author":"UK Prospective Diabetes Study Group","year":"1998","unstructured":"UK Prospective Diabetes Study Group: Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. BMJ 1998, 317:713\u2013720.","journal-title":"BMJ"},{"key":"25_CR32","doi-asserted-by":"crossref","first-page":"59","DOI":"10.4158\/EP.7.1.59","volume":"7","author":"DSH Bell","year":"2001","unstructured":"Bell DSH: Should angiotensin-converting enzyme inhibitors be added to the water supply of patients with diabetes? Endocr Pract 2001, 7:59\u201363. Documents the importance of ACE inhibitors to the type 1 and type 2 diabetic patient. Included are studies showing the ameliorating effects of ACE inhibitors on retinopathy, nephropathy, neuropathy, insulin resistance, and cardiovascular events.","journal-title":"Endocr Pract"},{"key":"25_CR33","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1056\/NEJM200001203420301","volume":"342","author":"S Yusuf","year":"2000","unstructured":"Yusuf S, Sleight P, Pogue J (Heart Outcomes Prevention Evaluation Study Investigators): Effects of an angiotensinconverting enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. New Engl J Med 2000, 342:145\u2013153. [Published errata appear in New Engl J Med 2000, 342:148; 2000, 342:1376.]","journal-title":"New Engl J Med"},{"key":"25_CR34","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1161\/01.CIR.103.7.919","volume":"103","author":"EM Lonn","year":"2001","unstructured":"Lonn EM, Yusuf S, Dzavik V, et al.: Effects of ramipril and vitamin E on atherosclerosis: the study to evaluate carotid ultrasound changes in patients treated with ramipril and vitamin E (SECURE). Circulation 2001, 103:919\u2013925.","journal-title":"Circulation"},{"key":"25_CR35","doi-asserted-by":"crossref","first-page":"51","DOI":"10.4158\/EP.5.1.51","volume":"5","author":"DSH Bell","year":"1999","unstructured":"Bell DSH: \u00df-adrenergic blocking agents in patients with diabetes-friend and foe. Endocr Pract 1999, 5:51\u201353. Documents both the increased cardioprotective properties of b blockers and their metabolic disadvantages, and suggests a solution to the problem.","journal-title":"Endocr Pract"},{"key":"25_CR36","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1016\/0735-1097(94)00543-Y","volume":"25","author":"SA Hall","year":"1995","unstructured":"Hall SA, Cigarroa CG, Marcoux L, et al.: Time course of improvements in left ventricular function mass and geometry in patients with congestive heart failure treated with betaadrenergic blockade. J Am Coll Cardiol 1995, 25:1154\u20131161.","journal-title":"J Am Coll Cardiol"},{"key":"25_CR37","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1111\/j.1464-5491.1994.tb02009.x","volume":"11","author":"WY Tse","year":"1994","unstructured":"Tse WY, Kendall M: Is there a role for beta-blockers in hypertensive diabetic patients? Diabet Med 1994, 11:137\u2013144.","journal-title":"Diabet Med"},{"key":"25_CR38","doi-asserted-by":"crossref","first-page":"955","DOI":"10.7326\/0003-4819-126-12-199706150-00004","volume":"126","author":"D Giugliano","year":"1997","unstructured":"Giugliano D, Acampora R, Marfella R, et al.: Metabolic and cardiovascular effects of carvedilol and atenolol in noninsulin- dependent diabetes mellitus and hypertension: a randomized controlled trial. Ann Intern Med 1997, 126:955\u2013959.","journal-title":"Ann Intern Med"},{"issue":"suppl 6","key":"25_CR39","doi-asserted-by":"crossref","first-page":"37","DOI":"10.2165\/00003495-198800366-00008","volume":"36","author":"B Tomlinson","year":"1988","unstructured":"Tomlinson B, Bompart F, Graham BR, et al.: Vasodilating mechanism and response to physiological pressor stimuli of acute doses of carvedilol compared with labetolol, propranolol, and hydralazine. Drugs 1988, 36(suppl 6):37\u201347.","journal-title":"Drugs"},{"key":"25_CR40","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1056\/NEJM199807233390404","volume":"339","author":"SM Haffner","year":"1998","unstructured":"Haffner SM, Lehto S, Ronnemaa T, et al.: Mortality from coronary heart disease in subjects with type 2 diabetes and in non-diabetic subjects with and without prior myocardial infarction. N Eng J Med 1998, 339:229\u2013234. This report emphasizes the high risk for cardiac events in the diabetic subject. It shows that a diabetic subject with no known heart disease has a higher risk of a cardiovascular event than a nondiabetic subject who has already had a myocardial infarction. Therefore, the term \u201cprimary prevention\u201d does not apply to the diabetic subject.","journal-title":"N Eng J Med"},{"key":"25_CR41","first-page":"271","volume":"6","author":"DSH Bell","year":"2000","unstructured":"Bell DSH: Inflammation, insulin resistance, infection, diabetes and atherosclerosis. Endocr Pract 2000, 6:271\u2013275.","journal-title":"Endocr Pract"},{"key":"25_CR42","doi-asserted-by":"crossref","first-page":"2513","DOI":"10.1161\/01.CIR.98.23.2513","volume":"98","author":"RB Goldberg","year":"1998","unstructured":"Goldberg RB, Mellies MJ, Sacks FM, et al.: Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the cholesterol and recurrent events (CARE) trial. The Care Investigators. Circulation 1998, 98:2513\u20132519.","journal-title":"Circulation"},{"key":"25_CR43","doi-asserted-by":"crossref","first-page":"614","DOI":"10.2337\/diacare.20.4.614","volume":"20","author":"K Pyorala","year":"1997","unstructured":"Pyorala K, Pedersen TR, Kjekshus J, et al.: Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary artery disease. Diabetes Care 1997, 20:614\u2013620.","journal-title":"Diabetes Care"},{"key":"25_CR44","first-page":"42","volume":"6","author":"S Feld","year":"2000","unstructured":"Feld S, Hellman R, Dickey RA, et al.: AACE Diabetes Guidelines. Endocr Pract 2000, 6:42\u201386.","journal-title":"Endocr Pract"},{"key":"25_CR45","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1056\/NEJM199908053410604","volume":"34","author":"HB Rubins","year":"1999","unstructured":"Rubins HB, Robins SJ, Collin D, et al. for the Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group: Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med 1999, 34:410\u2013418.","journal-title":"N Engl J Med"},{"key":"25_CR46","doi-asserted-by":"crossref","first-page":"8","DOI":"10.2337\/diab.34.1.8","volume":"34","author":"K Hiramatsu","year":"1985","unstructured":"Hiramatsu K, Bierman EC, Chart A: Metabolism of low-density lipoprotein from patients with diabetic hypertriglyceridemia by cultured skin fibroblasts. Diabetes 1985, 34:8\u201314.","journal-title":"Diabetes"},{"issue":"suppl 1","key":"25_CR47","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/0026-0495(79)90044-1","volume":"28","author":"JA Colwell","year":"1979","unstructured":"Colwell JA, Nain RM, Haluska PV, et al.: Platelet adhesion and aggregation in diabetes mellitus. Metab Clin Exp 1979, 28(suppl 1):394\u2013400.","journal-title":"Metab Clin Exp"},{"key":"25_CR48","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/0021-9150(93)90258-V","volume":"103","author":"A Araki","year":"1993","unstructured":"Araki A, Yoshiyusa S, Hideki I: Plasma homocysteine concentrations in Japanese patients with non-insulindependent diabetes mellitus: effect of parenteral methylcobalamin treatment. Atherosclerosis 1993, 103:149\u2013157.","journal-title":"Atherosclerosis"}],"container-title":["Current Diabetes Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11892-001-0025-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11892-001-0025-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11892-001-0025-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T23:52:05Z","timestamp":1559433125000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11892-001-0025-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,6]]},"references-count":48,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2001,6]]}},"alternative-id":["25"],"URL":"https:\/\/doi.org\/10.1007\/s11892-001-0025-7","relation":{},"ISSN":["1534-4827","1539-0829"],"issn-type":[{"value":"1534-4827","type":"print"},{"value":"1539-0829","type":"electronic"}],"subject":[],"published":{"date-parts":[[2001,6]]}}}